SARS‐CoV‐2 PLpro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment

Abstract The emergence of drug‐resistant viruses and novel strains necessitates the rapid development of novel antiviral therapies. This need was particularly demanding during the COVID‐19 pandemic. While de novo drug development is a time‐consuming process, repurposing existing approved medications...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	B.Sc. Sara Protić, M.Sc. Milica Crnoglavac Popović, M.Sc. Nevena Kaličanin, Dr. Olivera Prodanović, Dr. Milan Senćanski, Dr. Jelena Milićević, Dr. Kristina Stevanović, Dr. Vladimir Perović, Dr. Slobodan Paessler, Dr. Radivoje Prodanović, Dr. Sanja Glišić
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Wiley-VCH 2024-11-01
Reeks:	ChemistryOpen
Onderwerpen:	antiviral therapy drug repurposing fidaxomicin SARS-CoV-2 PLpro in vitro
Online toegang:	https://doi.org/10.1002/open.202400091
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!